Aura Biosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 89
- Market Cap
- -
- Introduction
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
FDA Accepts Satsuma and SNBL's NDA Resubmission for STS101 Migraine Treatment
The FDA has accepted for review Satsuma Pharmaceuticals and SNBL's resubmitted NDA for STS101, a dihydroergotamine nasal powder, for acute migraine treatment.
sTMS Shows Promise for Migraine Prevention in Open-Label Study
A multicenter, prospective, open-label study suggests that single-pulse transcranial magnetic stimulation (sTMS) may be an effective preventive treatment for migraine.